Can an effective SARS-CoV-2 vaccine be developed for the older population?

Graham Pawelec¹,²* and Nan-ping Weng³*

Abstract
The emergence of SARS-CoV-2 and its inordinately rapid spread is posing severe challenges to the wellbeing of millions of people worldwide, health care systems and the global economy. While many younger people experience no or mild symptoms on infection, older adults are highly susceptible to life-threatening respiratory and systemic conditions which demand a full understanding and leveraging of knowledge of the differences between immunity in young and old people. Consequently, we welcome papers addressing any issues relevant to immunity and ageing in the context of SARS-CoV-2, and will endeavour to fast-track peer-review. We aim to provide a platform exclusively for discussions of individual and age differences in susceptibility and immune responses to COVID caused by SARS-CoV-2 infection and how to prevent or reduce severity of disease in older adults.

Keywords: Severe acute respiratory syndrome, SARS-CoV-2, Immunosenescence, Vaccination, COVID

Introduction
The newly-emerged Coronavirus SARS-CoV-2 is highly infectious and has rapidly spread throughout the world with a case fatality rate (CFR) highly dependent on age and pre-existing conditions associated with age. As more data become available, average CFRs in children appear negligible, in young adults perhaps up to 1%, but in people over 60 rising to 4%, over 70 up to 9% and over 80 even up to 18% (see, for example, https://www.cebm.net/covid-19/global-covid-19-case-fatality-rates/). Clearly, these figures can vary tremendously from country to country, and depend on the state of health of the patients and the state of the health care system, but it is likely that this sort of age stratification reflects the general characteristics of Coronavirus disease (COVID). Obviously, there is vigorous debate as to why this may be, but a common denominator is the waning of immunity with age. Although much effort is currently directed at repurposing licensed drugs as anti-virals, particularly those with anti-inflammatory effects [1] this is usually viewed as a stop-gap measure and hopes are pinned on developing effective vaccines. An unprecedented worldwide effort is channelling academic and industrial resources into the rapid production and testing of SARS-CoV-2 vaccines. Quite apart from the potential dangers of accelerated vaccine development [2], and remembering the additional danger of immune enhancement [3], even were this successful the question remains whether the most susceptible members of the population (say, those over 60) would benefit.

COVID immunopathology and potential interventions
There is no pre-existing immunity to a virus not previously encountered except via cross-reactivity or shared viral antigen, as is sometimes the case for seasonal influenza strains. As SARS-CoV-2 is almost certainly completely novel for at least the vast majority of people, the virus enjoys unrestrained entry into host cells which then rely on intracellular (cell-intrinsic) anti-viral defence mechanisms [4]. If these fail, cell death releases damage-associated molecules (DAMPs) and viral particles triggering inflammatory reactions. Severe acute

* Correspondence: graham.pawelec@uni-tuebingen.de; wengn@grc.nia.nih.gov
1Department of Immunology, University of Tübingen, Tübingen, Germany
2National Institute on Aging, Baltimore, MD, USA
Full list of author information is available at the end of the article

© The Author(s). 2020. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
respiratory syndrome is caused by dysregulated over-
exuberant inflammatory responses that can progress to a
systemic sepsis-like “cytokine storm” [5], which together
with effects of the virus also directly infecting other or-
gans, not just the lung, can result in multiple organ fail-
ure. The aim of prophylactic vaccination of course is to
induce sufficient neutralising antibody to prevent infec-
tion and sufficient numbers of virus-specific resident
memory cytotoxic T cells in the lung to prevent viral
replication. This requires the presence and efficient co-
operation of antigen-presenting cells, T cells and B cells
within a correctly functioning microenvironment (lymph
node). When vaccination is unable to elicit qualitatively
or quantitatively sufficient protective antibody, host cell
infection will still take place, and may trigger sequelae
described above. Given the rapidity and degree with
which SARS-CoV-2 can cause immunopathology in the
lung, vaccines would have to be highly efficient in gener-
ating neutralising antibody as well as protective cell me-
diated local immunity to prevent this sequence of
events. Achieving such immune protection by a vaccine
is quite feasible in the young, but it may prove to be
challenging in old populations as evidenced by the low
efficacy of seasonal influenza vaccine in such popula-
tions. Alternatively, adoptive immunotherapy with neu-
tralising monoclonal antibody, as in cancer treatment,
may be a possibility, and several companies are working
on this. However, repeated i.v. infusion of sufficient anti-
body does not seem a priori an optimal approach.
Clearly, traditional vaccination to stimulate the patient’s
own response would be preferable, but how likely is it
that that could be accomplished in older people?

Immunosenescence and its underlying mechanisms

Altered immune competence with increasing age, so-
called immunosenescence [6], is the result of changes at
multiple levels of the immune system over time. It in-
cludes the altered balance of immune cell production in
the bone marrow resulting in reduced lymphopoiesis
and increased output of myeloid lineage cells which are
also functionally compromised. Thymic involution sub-
stantially reduces the output of naïve T cells and the
TCR repertoire contracts over time. Although loss of cir-
culating naïve B cells is less profound than naïve T cells,
reduced BCR repertoire diversity with age is also well
recognized. Furthermore, aging is associated with the
dysfunction of innate immune cells like neutrophils at
sites of infection possibly due to the poorer capacity of
the adaptive immune system to reign in over-exuberant
inflammatory responses. The ability to generate adaptive
immune responses is compromised by dysfunction of
antigen-presenting cells and disorganised and fibrotic
lymph node architecture. Collectively, these changes pre-
vent appropriate control of the initial inflammatory
response and decrease the generation of an efficient and
robust adaptive immune response which requires the
production of large number of functional effector T cells
and B cells. For all these reasons, protective responses to
infection or vaccination tend to be on average lower in
many older adults than in the young, but there is enor-
mous inter-individual variation in people owing to the
individual variations of genetics and the history of envir-
onmental exposures. Hence, two crucial questions are
raised by these considerations: 1) how can we measure
immune and physiological status in an individual in a
clinically meaningful manner and 2) how can we inter-
vene at the crucial checkpoints thus identified in order
to restore appropriate immune function? Identification
of biomarkers of protective or detrimental responses to
a SARS-CoV-2 infection or vaccine and determination
of the kinetic pattern of these biomarkers during the
course of infection or vaccine response are critical to ad-
dress these questions.

Biomarkers and vaccine requirement

There are few precedents to assist us here. Efforts to de-
velop a prophylactic vaccine or SARS-CoV-1 were shelved
when the infection faded by itself. There are surprisingly
few data available concerning the status of immune respon-
siveness to truly novel antigens in humans. A study on Ye-
llow Fever vaccination of the elderly pointed to
dysfunctional antigen-presenting cells and a dearth of
antigen-specific CD4+ Th helper cells as culprits in the low
antibody responses of older vaccinees [7]. Otherwise, we
have to rely mostly on the large literature on seasonal influ-
enza vaccination. However, the problem here is that every-
one has already been exposed to some strains of influenza
and even newly-emerging strains such as the avian H7N1
are not entirely novel. Nonetheless, knowledge garnered on
immunity and responses to vaccination against this virus
may tell us something about the capacity of older adults to
respond to SARS-CoV-2. Primate models featuring the re-
sponses of older monkeys to SARS-CoV-1 infection may
also be informative [8]. A systems biology approach will be
needed to identify the protective antigen/epitopes of SARS-
CoV-2 for both antibody/B cell responses and T cell re-
sponses and to classify them as protective or non-protective
responses to serve as useful biomarkers. Importantly, vac-
cine design for the older adult should aim to stimulate a
broad T and B cell response potentially overcoming re-
duced immune function in the older population.

How can current immunological knowledge be leveraged
to protect the oldest old against COVID?

According to the above arguments, we consider it un-
likely that a conventional vaccine based on young adult
responses will be highly effective in COVID prophylaxis
for older adults, but should be rigorously applied to
everyone else to achieve herd immunity that will indirectly protect the elderly. The ability to prevent infection by adoptive immunotherapy remains a possibility, albeit logistically and financially challenging. Pharmacological prevention of infection by other means, for example, by blocking the interactions between viral proteins and host cell molecules acting as receptors may be useful. Finally, various ways to improve the general immune functions in the older population should be considered and developed to strengthen the immune response to infection and vaccine in general. These approaches could include interventions at the level of hematopoiesis to correct the skewing of output towards dysfunctional myeloid cells responsible for acute inflammatory responses in the lung, normalisation of T cell progenitor output and reconstitution of the thymus for correct selection of T cells, especially regulatory T cells to keep inflammation in check, reconstitution of antigen presentation function in the lymph nodes and re-alignment of T-B cell interactions and functionality. In the meantime, the major benefit of vaccination will be seen at the population level in younger people. Once herd immunity is established, the well-known effect of diluting out new hosts for acute viruses should result in the virus disappearing, with the proviso that protective immunity is retained for long enough (this is not yet established) and reinfection is not introduced from a location where new hosts were still available. And with the linked proviso that the virus does not mutate into a form against which immune memory is not present.

We welcome papers addressing any of the issues discussed above and will endeavour to fast-track peer review to provide a platform exclusively for discussions of individual and age differences in immune responses SARS-CoV-2 and susceptibility to COVID and how to prevent or reduce severity of disease in older adults.

Acknowledgements
None.

Authors’ contributions
Both authors wrote and revised the manuscript. The author(s) read and approved the final manuscript.

Authors’ information
No further information.

Funding
No specific funding.

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Both Co-Editors-in-Chief consent to publication.

Competing interests
Both authors declare no competing interests.

Author details
1Department of Immunology, University of Tübingen, Tübingen, Germany.
2Health Sciences North Research Institute, Sudbury, Ontario, Canada.
3National Institute on Aging, Baltimore, MD, USA.

Received: 31 March 2020 Accepted: 3 April 2020
Published online: 11 April 2020

References
1. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–2.
2. Jiang S. Don’t rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees. Nature. 2020;579(7799):321.
3. Wan Y, Shang J, Sun S, Tai W, Chen J, Geng Q, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol. 2020;94(5). https://doi.org/10.1128/JVI.00215-19. Print 2020 Feb 14.
4. Ma Z, Damania B. The cGAS-STING defense pathway and its counteraction by viruses. Cell Host Microbe. 2016;19(2):150–8.
5. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529–39.
6. Crooke SN, Ovsyannikova KS, Poland GA, Kennedy RB. Immunosenescence and human vaccine immune responses. Immun Ageing. 2019;16:25.
7. Schulz AR, Malzer JN, Domingo C, Jurchott K, Grutzkau A, Babel N, et al. Low Thymic activity and dendritic cell numbers are associated with the immune response to primary viral infection in elderly humans. J Immunol. 2015;195(10):4699–711.
8. Clay CC, Donant N, Fomukong N, Knight JB, Overheim K, Tipper J, et al. Severe acute respiratory syndrome-coronavirus infection in aged nonhuman primates is associated with modulated pulmonary and systemic immune responses. Immun Ageing. 2014;11(1):4.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.